Business Context and Reporting Period
Company: ANAVEX LIFE SCIENCES CORP.
Filing Type: Form 8-K (Current Report)
Date of Report: September 13, 2019
Reporting Period: Event date of September 13, 2019
This filing reports the submission of a prospectus supplement to an effective Form S-3 registration statement (File No. 333-232550). The supplement registers shares of common stock issuable pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC. The primary purpose of this 8-K is to include the attached opinion of counsel regarding the legality of these shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding securities registration and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial performance or operational status are reported in this document. The only material event is the administrative filing of a prospectus supplement to facilitate the issuance of common stock under an existing purchase agreement.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the report is being filed solely to include the opinion of counsel (Exhibit 5.1) attached hereto.
Risks and Contingencies: No specific risks, contingencies, or unusual items are disclosed in the text of this filing.
Guidance: No forward-looking guidance or outlook is provided.
Investor Verification Checklist
- Verify the terms of the purchase agreement with Lincoln Park Capital Fund, LLC referenced in the prospectus supplement.
- Review the attached Exhibit 5.1 (Opinion of Snell & Wilmer, L.L.P.) for legal validation of the share issuance.
- Confirm the total number of shares registered under the Form S-3 (File No. 333-232550) to assess potential dilution.
- Check subsequent filings for the actual execution of the share issuance and capital raised.